logo image
search icon
Global Minimal Residual Disease Market

Minimal Residual Disease Market, Share & Trends Analysis Report, By Product (Assay Kits & Reagents, Instruments), By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Flow Cytometry, Other Technologies), By Application (Hematological Malignancies, Lymphoma, Solid Tumors, Multiple Myeloma, Other Applications), By End User, By Region, and Segment Forecasts, 2025-2034

Report ID : 1448 | Published : 2025-05-16 | Pages: 180 | Format: PDF/EXCEL/Power BI Dashbord

Global Minimal Residual Disease Market Size is valued at USD 1.4 Bn in 2024 and is predicted to reach USD 4.6 Bn by the year 2034 at a 12.8% CAGR during the forecast period for 2025-2034.

Key Industry Insights & Findings from the Report:

  • Precision oncology, which tailors cancer treatment to the molecular characteristics of an individual's cancer, is a key driver of the MRD market.
  • Increasing the sensitivity of MRD detection methods contributes to increasing the accuracy of treatment response assessment.
  • North America dominated the market and accounted for a revenue share of global revenue in 2024.

 minimal recedue

The sophisticated nature of MRD detection methods, including next-generation sequencing (NGS), flow cytometry, and polymerase chain reaction (PCR), present challenges Minimal residual disease, also known as measurable residual disease or MRD, refers to the preclinical stages of diseases such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and multiple myeloma (MM). After treatment, the cancer cells that remain in the body are referred to as a minimal residual disease. These cancer cells are undetected by imaging or physical exams, but sophisticated laboratory tests can discover them. The minimal residual disease is an essential indicator of disease progression and therapy response. The growing importance of the test is expected to drive growth in the worldwide minimum residual disease market in the coming years.

The global incidence of cancer has increased dramatically, which is projected to play a vital role in expanding the global minimal residual illness market. Patients are expected to see more precision in treatment using novel technology. These factors are likely to have an impact on growth. Furthermore, favorable government and private-sector initiatives for developing and adopting NGS technologies, technological advancements in cloud computing and data integration, and the availability of a technologically advanced healthcare research framework are all stimulating market growth. Additionally, the improved regulatory and reimbursement landscape for NGS-based diagnostic tests and increased genome mapping initiatives will fuel market expansion throughout the forecast period.

Market Segmentation:

The minimal residual disease market is segmented on the product, technology, application and end user. Based on product, the minimal residual disease market is divided into assay kits & reagents, instruments. Based on the technology, the minimal residual disease market is divided into polymerase chain reaction, next-generation sequencing, flow cytometry, and other technologies. Based on the Application, the minimal residual disease market is segmented into hematological malignancies, lymphoma, solid tumors, multiple myeloma, and other applications. Based on the end user, the minimal residual disease market is segmented into hospitals & specialty clinics, diagnostic laboratories, academic & research institutes, and other end users.

The Assay Kits & Reagents segment is accounted as a major contributor to the minimal residual disease market.

Based on product, the minimal residual disease market is divided into assay kits & reagents, instruments. Among these, The Assay Kits & Reagents segment leads the MRD detection market due to its frequent and recurring use, as each test requires fresh reagents and assay kits. This segment benefits from the growing demand for repeat testing to monitor MRD levels during and after treatment, making it essential for effective disease management. Additionally, the expanding use of MRD detection in personalized medicine and clinical trials further fuels the demand for these consumables. In contrast, instruments such as flow cytometers and PCR machines represent a smaller yet stable market share, primarily driven by infrastructure investment rather than test volume.

The Polymerase Chain Reaction segment witnessed growth at a rapid rate.

Based on the technology, the minimal residual disease market is divided into polymerase chain reaction, next-generation sequencing, flow cytometry, and other technologies. Among these, the Polymerase Chain Reaction (PCR) segment has traditionally dominated the MRD detection market due to its widespread use, high specificity, and cost-effectiveness in routine clinical monitoring. However, Next-Generation Sequencing (NGS) is emerging as the fastest-growing segment, driven by its ultra-high sensitivity and ability to detect a broad spectrum of genetic alterations, making it increasingly favored in clinical trials and personalized treatment approaches. Flow cytometry also holds a significant share, especially in acute leukemias, offering rapid and relatively affordable results, though with lower sensitivity. 

The North American Minimal Residual Disease Market Holds A Significant Regional Revenue Share.

The North American minimal residual disease market is expected to register the highest market share in revenue shortly. The rising prevalence of blood malignancies and the increased investment in MRD research by government and private groups have grown healthcare affordability in the United States and the rise in knowledge and awareness among individuals in this region. In addition, Asia Pacific is projected to grow rapidly in the global minimal residual disease market due to government initiatives and large-scale genome sequencing studies funding to develop targeted treatments to contribute to market growth. Furthermore, the existence of key organizations and industries and the quick spread of paternity testing, genealogy, and personal health awareness drive market growth in this area over the forecast period.

Recent Developments:

  • In Feb 2022, Personalis, Inc. and the Moores Cancer Center at the University of California San Diego Health partnered to offer clinical diagnostic testing for patients with advanced solid tumours and haematological malignancies. The Moores Cancer Center is recognized as a Comprehensive Cancer Center by the National Cancer Institute. The relationship facilitated the integration of Personalis' advanced and extensive genomic tumour profiling test into the healthcare services provided by UC San Diego. This enabled healthcare professionals and cancer patients to benefit from the test's ability to inform FDA-approved therapy decisions and provide access to potential treatment options in clinical trials.

Competitive Landscape

Some major key players in the Minimal Residual Disease Market:

  • Adaptive Biotechnologies,
  • ARUP Laboratories,
  • Bio-Rad Laboratories Inc.,
  • Cergentis B.V.,
  • Hoffmann-La Roche Ltd.,
  • ICON Plc,
  • Invivoscribe Inc.,
  • Laboratory Corporation of America Holdings,
  • Mission Bio,
  • Natera Inc.,
  • NeoGenomics Laboratories,
  • OPKO Health Inc.,
  • Sysmex Corporation

Minimal Residual Disease Market Report Scope:

Report Attribute

Specifications

Market Size Value In 2024

USD 1.4 Bn

Revenue Forecast In 2034

USD 4.6 Bn 

Growth Rate CAGR

CAGR of 12.8% from 2025 to 2034

Quantitative Units

Representation of revenue in US$ Bn,and CAGR from 2025 to 2034

Historic Year

2021 to 2024

Forecast Year

2025-2034

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

Product, Technology, Application

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ; France; Italy; Spain; South Korea; South East Asia; 

Competitive Landscape

F. Hoffmann-La Roche Ag, Laboratory Corporation of America Holdings, Guardant Health, Inc, Sysmex Corporation, NEOGENOMICS Laboratories, MOLECULARMD, Adaptive Biotechnologies, ARCHERDX, Bio-Rad Laboratories, Inc, Natera, Inc, OPKO Health, Inc, GENETRON Health, Quest Diagnostics, Inc, ASURAGEN, Inc, INVIVOSCRIBE, Inc, Arup Laboratories Inc, Mission Bio, Inc, ERGENTIS B.V

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Minimal Residual Disease Market Snapshot

Chapter 4. Global Minimal Residual Disease Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Minimal Residual Disease Market Industry Trends

4.10. Global Minimal Residual Disease Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Minimal Residual Disease Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. Market Share by Product, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Assay Kits & Reagents
5.2.2. Instruments

Chapter 6. Minimal Residual Disease Market Segmentation 2: By Technology, Estimates & Trend Analysis
6.1. Market Share by Technology, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Technology:

6.2.1. Polymerase Chain Reaction
6.2.2. Next-Generation Sequencing
6.2.3. Flow Cytometry
6.2.4. Other Technologies

Chapter 7. Minimal Residual Disease Market Segmentation 3: By Application, Estimates & Trend Analysis
7.1. Market Share by Application, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:

7.2.1. Hematological Malignancies
7.2.1.1. Leukemia
7.2.1.1.1. Myeloid Leukemia
7.2.1.1.2. Lymphocytic Leukemia
7.2.1.1.3. Other Leukemias
7.2.1.2. Lymphoma
7.2.1.2.1. Non-Hodgkin Lymphoma
7.2.1.2.2. Hodgkin Lymphoma
7.2.2. Solid Tumors
7.2.3. Multiple Myeloma
7.2.4. Other Applications

Chapter 8. Minimal Residual Disease Market Segmentation 3: By End User, Estimates & Trend Analysis
8.1. Market Share by End User, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End User:

8.2.1. Hospitals & Specialty Clinics
8.2.2. Diagnostic Laboratories
8.2.3. Academic & Research Institutes
8.2.4. Other End Users

Chapter 9. Minimal Residual Disease Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Minimal Residual Disease Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.2.3. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.2.4. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.2.5. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034

9.3. Europe
9.3.1. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.3.3. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.3.4. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.3.5. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034

9.4. Asia Pacific
9.4.1. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.4.3. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.4.4. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.4.5. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034

9.5. Latin America
9.5.1. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.5.3. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.5.4. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.5.5. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034

9.6. Middle East & Africa
9.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.6.3. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.6.4. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.6.5. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034

Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles

10.2.1. F. Hoffmann-La Roche Ag

10.2.1.1. Business Overview
10.2.1.2. Key Product/Service Overview
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy

10.2.2. Laboratory Corporation Of America Holdings

10.2.3. Guardant Health, Inc.
10.2.4. Sysmex Corporation
10.2.5. NEOGENOMICS Laboratories
10.2.6. MOLECULARMD (A Subsidiary Of Icon Plc)
10.2.7. Adaptive Biotechnologies
10.2.8. ARCHERDX (Invitae Corporation)
10.2.9. Bio-Rad Laboratories, Inc.
10.2.10. Natera, Inc.
10.2.11. OPKO Health, Inc.
10.2.12. GENETRON Health
10.2.13. Quest Diagnostics, Inc.
10.2.14. ASURAGEN, Inc.
10.2.15. INVIVOSCRIBE, Inc.
10.2.16. Arup Laboratories Inc.
10.2.17. Mission Bio, Inc.
10.2.18. CERGENTIS B.V.

Segmentation Of Minimal Residual Disease Market

Minimal Residual Disease Market By Product

  • Assay Kits & Reagents
  • Instruments

 minimal recidual

Minimal Residual Disease Market By Technology

  • Polymerase Chain Reaction
  • Next-Generation Sequencing
  • Flow Cytometry
  • Other Technologies

Minimal Residual Disease Market By Application

  • Hematological Malignancies
    • Leukemia
      • Myeloid Leukemia
      • Lymphocytic Leukemia
      • Other Leukemias
    • Lymphoma
      • Non-Hodgkin Lymphoma
      • Hodgkin Lymphoma
    • Solid Tumors
    • Multiple Myeloma
    • Other Applications

Minimal Residual Disease Market By End User

  • Hospitals & Specialty Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Other End Users

By Region-

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Minimal Residual Disease Market Size?

Global Minimal Residual Disease Market is expected to grow at a 12.8% CAGR during the forecast period for 2025-2034

Adaptive Biotechnologies, ARUP Laboratories, Bio-Rad Laboratories Inc., Cergentis B.V., F. Hoffmann-La Roche Ltd., ICON Plc, Invivoscribe Inc., Labora

Product, technology, application and end user are the key segments of the Minimal Residual Disease Market.

North America region is leading the Minimal Residual Disease Market

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Report License Selection

Determine the appropriate license for your report

Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach